SEARCH

SEARCH BY CITATION

References

  • [1]
    Shanahan, F. (2002) Crohn's disease. Lancet 359, 6269.
  • [2]
    Duchmann, R., Kaiser, I., Hermann, E. et.al. (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin. Exp. Immunol. 102, 448455.
  • [3]
    Steidler, L., Hans, W., Schotte, L. et.al. (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin 10. Science 289, 13521354.
  • [4]
    van Deventer, S.J., Elson, C.O., Fedorak, R.N. (1997) Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 113, 383389.
  • [5]
    Shanahan, F. (2000) Therapeutic manipulation of gut flora. Science 289, 13111312.
  • [6]
    Dunne, C., Murphy, L., Flynn, S. et.al. (1999) Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie van Leeuwenhoek 76, 279292.
  • [7]
    Gionchetti, P., Rizzello, F., Venturi, A. et.al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind placebo-controlled trial. Gastroenterology 119, 305309.
  • [8]
    Gionchetti, P., Rizzello, F., Helwig, U. et.al. (2003) Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology 124(5), 12021209.
  • [9]
    Ulisse, S., Gionchetti, P., D'Alo, S. et.al. (2001) Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am. J. Gastroenterol. 96, 26912699.
    Direct Link:
  • [10]
    Madsen, K.L., Doyle, J.S., Jewell, L.D. et.al. (1999) Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116, 11071114.
  • [11]
    Madsen, K.L., Cornish, A., Soper, P. et.al. (2001) Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121, 580591.
  • [12]
    Lammers, K.M., Helwig, U., Swennen, E. et.al. (2002) Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am. J. Gastroenterol. 97, 11821186.
    Direct Link:
  • [13]
    Krieg, A.M. (2002) CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709760.
  • [14]
    Brigidi, P., Vitali, B., Swennen, E. et.al. (2000) Specific detection of Bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction. Syst. Appl. Microbiol. 23, 391399.
  • [15]
    Hartemink, R., Domenech, V.R., Rombouts, F.M. (1997) LAMVAB a new selective medium for the isolation of lactobacilli from feces. J. Microbiol. Methods 29, 7784.
  • [16]
    Hartemink, R., Kok, B.J., Weenk, G.H. et.al. (1996) Raffinose-Bifidobacterium (RB) agar, a new selective medium for bifidobacteria. J. Microbiol. Methods 27, 3343.
  • [17]
    Dave, R.I., Shah, N.P. (1996) Evaluation of media for selective enumeration of Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus acidophilus, and bifidobacteria. J. Dairy Sci. 76, 15291536.
  • [18]
    Alander, M., Satokari, R., Korpela, R. et.al. (1999) Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl. Environ. Microbiol. 65, 351354.
  • [19]
    Krieg, A.M., Yi, A.K., Matson, S. et.al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546549.
  • [20]
    Gilkeson, G.S., Conover, J., Halpern, M. et.al. (1998) Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice. J. Immunol. 161, 38903895.
  • [21]
    Campieri, M., Gionchetti, P. (1999) Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative Gastroenterology 116, 12461249.
  • [22]
    Rachmilewitz, D., Karmeli, F., Takabayashi, K. et.al. (2002) Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 122, 14281441.
  • [23]
    Agrawal, S., Kandimalla, E.R. (2002) Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med. 8, 114126.